Telisotuzumab vedotin is a <i>MET</i>-targeting antibody-drug conjugate that has demonstrated a good treatment response in patients with <i>EGFR</i> wild-type MET-overexpressing non-squamous non-small cell lung cancer. This evidence concerns the gene EGFR and non-small cell squamous lung carcinoma.